Allarity Therapeutics(ALLR)

Focus: Allarity Therapeutics is a Boston-based public oncology company focused on cancer treatments paired with companion diagnostics, particularly its proprietary Drug Response Predictor (DRP) platform. The company operates at the intersection of therapeutics and precision medicine diagnostics for solid tumors and hematologic malignancies.

Oncology

Profile data last refreshed 16h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Allarity Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Allarity Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

4/9 — Basic

Company HealthSolid

Pipeline

Early-stage

6 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$0K

FY2025

Pipeline & Clinical Trials

Drug Response Predictor

Ovarian Cancer

N/A

Clinical Trials (2)

NCT03643107Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)

Phase 2

Help build intelligence for Allarity Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Innovative companion diagnostic model: Recently achieved CLIA certification (July 2026) for the DRP platform, positioning the company to advance precision oncology testing and differentiate from traditional pharma competitors.
Focused oncology pipeline with Phase 2 momentum: 2X-121 for metastatic breast cancer is the most advanced program across 3 trials, indicating active clinical development and near-term data readouts.
Publicly traded with improved cash position: FY 2025 cash rose to $20M (vs. $166K in FY 2024), suggesting recent capital raise and runway extension to fund pipeline progression.

Watch Out For

Pre-revenue stage with accelerating burn: Net losses widened to -$24.5M in FY 2025 (vs. -$11.9M in FY 2024) on only $6M R&D spend, indicating operational inefficiency and sustainability concerns.
No active hiring and zero open roles: The activeJobCount of 0 signals organizational freeze or severe headcount constraints, limiting career mobility and team expansion opportunities.
Early-stage pipeline with no Phase 3 programs: All 6 pipeline programs remain in Phase 1/2, with 5 total clinical trials—highest-risk profile with multi-year timeline to potential approvals.

Generated by Claude from Allarity Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

NCT03877796Clinical Pre-screening Protocol for Ovarian Cancer

N/A

APO010

Relapsed/Refractory Multiple Myeloma

Phase 1/2

Clinical Trials (1)

NCT03196947Safety and Pharmacokinetics of Rising Doses of APO010 in Relapsed/Refractory Multiple Myeloma Patients Selected by DRP

Phase 1/2

LiPlaCis

Advanced or Refractory Solid Tumours

Phase 1/2

Clinical Trials (1)

NCT01861496Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours

Phase 1/2

2X-121

Metastatic Breast Cancer

Phase 2

Clinical Trials (3)

NCT03878849Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer

Phase 2

NCT03562832Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP

Phase 2

NCT05571969Study of PARPi 2X-121 as Monotherapy and in Combination With Dovitinib in Patients With Advanced Solid Tumors

Phase 1

Ixabepilone

Metastatic Breast Cancer

Phase 2

Clinical Trials (1)

NCT04796324Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP.

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 8 clinical trials

Top TAs: Oncology

Publications: 5 in PubMed

SEC Filings: 2 available

Therapeutic Area Focus

Oncology

8 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

R&D Spend

$6M14%

Net Income

-$25M

Cash

Research Publications(5)

Recent peer-reviewed publications with author affiliations at this company

A novel drug specific mRNA biomarker predictor for selection of patients responding to dovitinib treatment of advanced renal cell carcinoma and other solid tumors.

PloS one

2023

PMID:37647320

Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.

European journal of cancer (Oxford, England : 1990)

2022

PMID:35863108

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Allarity Therapeutics(ALLR)

About Allarity Therapeutics

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Recent News · Allarity Therapeutics(10)

Open Jobs (0)

Financials (FY2025)

Research Publications(5)